IBDEI1UT ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,32640,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32640,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,Not in Remission
 ;;^UTILITY(U,$J,358.3,32640,1,4,0)
 ;;=4^C92.60
 ;;^UTILITY(U,$J,358.3,32640,2)
 ;;=^5001807
 ;;^UTILITY(U,$J,358.3,32641,0)
 ;;=C92.A1^^182^1992^9
 ;;^UTILITY(U,$J,358.3,32641,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32641,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,In Remission
 ;;^UTILITY(U,$J,358.3,32641,1,4,0)
 ;;=4^C92.A1
 ;;^UTILITY(U,$J,358.3,32641,2)
 ;;=^5001814
 ;;^UTILITY(U,$J,358.3,32642,0)
 ;;=C92.A0^^182^1992^10
 ;;^UTILITY(U,$J,358.3,32642,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32642,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,Not in Remission
 ;;^UTILITY(U,$J,358.3,32642,1,4,0)
 ;;=4^C92.A0
 ;;^UTILITY(U,$J,358.3,32642,2)
 ;;=^5001813
 ;;^UTILITY(U,$J,358.3,32643,0)
 ;;=C92.51^^182^1992^11
 ;;^UTILITY(U,$J,358.3,32643,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32643,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,32643,1,4,0)
 ;;=4^C92.51
 ;;^UTILITY(U,$J,358.3,32643,2)
 ;;=^5001805
 ;;^UTILITY(U,$J,358.3,32644,0)
 ;;=C92.50^^182^1992^12
 ;;^UTILITY(U,$J,358.3,32644,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32644,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,32644,1,4,0)
 ;;=4^C92.50
 ;;^UTILITY(U,$J,358.3,32644,2)
 ;;=^5001804
 ;;^UTILITY(U,$J,358.3,32645,0)
 ;;=C94.40^^182^1992^15
 ;;^UTILITY(U,$J,358.3,32645,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32645,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
 ;;^UTILITY(U,$J,358.3,32645,1,4,0)
 ;;=4^C94.40
 ;;^UTILITY(U,$J,358.3,32645,2)
 ;;=^5001843
 ;;^UTILITY(U,$J,358.3,32646,0)
 ;;=C94.42^^182^1992^13
 ;;^UTILITY(U,$J,358.3,32646,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32646,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
 ;;^UTILITY(U,$J,358.3,32646,1,4,0)
 ;;=4^C94.42
 ;;^UTILITY(U,$J,358.3,32646,2)
 ;;=^5001845
 ;;^UTILITY(U,$J,358.3,32647,0)
 ;;=C94.41^^182^1992^14
 ;;^UTILITY(U,$J,358.3,32647,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32647,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
 ;;^UTILITY(U,$J,358.3,32647,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,32647,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,32648,0)
 ;;=D62.^^182^1992^16
 ;;^UTILITY(U,$J,358.3,32648,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32648,1,3,0)
 ;;=3^Acute Posthemorrhagic Anemia
 ;;^UTILITY(U,$J,358.3,32648,1,4,0)
 ;;=4^D62.
 ;;^UTILITY(U,$J,358.3,32648,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,32649,0)
 ;;=C92.41^^182^1992^17
 ;;^UTILITY(U,$J,358.3,32649,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32649,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,32649,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,32649,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,32650,0)
 ;;=C92.40^^182^1992^18
 ;;^UTILITY(U,$J,358.3,32650,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32650,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,32650,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,32650,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,32651,0)
 ;;=D56.0^^182^1992^19
 ;;^UTILITY(U,$J,358.3,32651,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32651,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,32651,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,32651,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,32652,0)
 ;;=D63.1^^182^1992^21
 ;;^UTILITY(U,$J,358.3,32652,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32652,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;
 ;;$END ROU IBDEI1UT
